

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/E300B5F8723EN.html>

Date: May 2021

Pages: 55

Price: US\$ 125.00 (Single User License)

ID: E300B5F8723EN

Abstracts

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Epizyme Inc (Epizyme) discovers, develops and markets novel epigenetic therapies for the treatment of cancer and other disorders. The company's marketed product includes, Tazverik (tazemetostat) is an oral, first-in-class, small molecule inhibitor of the EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. It pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

May 06,2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

Apr 29,2021: Epizyme Announces Date of First Quarter 2021 Financial Results

Mar 02,2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company's strategic vision call

Feb 23,2021: Epizyme provides business update and reports fourth quarter and full year

2020 financial results

Feb 16,2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Epizyme Inc - Key Facts
- Epizyme Inc - Key Employees
- Epizyme Inc - Key Employee Biographies
- Epizyme Inc - Major Products and Services
- Epizyme Inc - History
- Epizyme Inc - Company Statement
- Epizyme Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
- Epizyme Inc - Business Description
- Other Break-up: Collaboration Revenue
- Performance
- Other Break-up: Product Revenue
- Performance
- R&D Overview
- Epizyme Inc - Corporate Strategy
- Epizyme Inc - SWOT Analysis
- SWOT Analysis - Overview
- Epizyme Inc - Strengths
- Epizyme Inc - Weaknesses
- Epizyme Inc - Opportunities
- Epizyme Inc - Threats
- Epizyme Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Epizyme Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 06, 2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

Apr 29, 2021: Epizyme Announces Date of First Quarter 2021 Financial Results

Mar 02, 2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call

Feb 23, 2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results

Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences

Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences

Nov 06, 2020: Epizyme reports business progress and third quarter 2020 financial results

Aug 04, 2020: Epizyme reports business progress and second quarter 2020 financial results

May 04, 2020: Epizyme reports business progress and first quarter 2020 financial results

Mar 20, 2020: Epizyme appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Epizyme Inc, Key Facts
Epizyme Inc, Key Employees
Epizyme Inc, Key Employee Biographies
Epizyme Inc, Major Products and Services
Epizyme Inc, History
Epizyme Inc, Subsidiaries
Epizyme Inc, Key Competitors
Epizyme Inc, Ratios based on current share price
Epizyme Inc, Annual Ratios
Epizyme Inc, Annual Ratios (Cont...1)
Epizyme Inc, Interim Ratios
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Epizyme Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Epizyme Inc, Performance Chart (2016 - 2020)

Epizyme Inc, Ratio Charts

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/E300B5F8723EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E300B5F8723EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970